LLY · Eli Lilly and Company
$1115.70
-0.65% last session
End-of-day data · close of 2026-09-11
Market cap
$994B
Enterprise value
$1,040B
Trailing P/E
37.5
Forward P/E
23.6
Dividend yield
1.0%
Beta
0.50
Avg volume
3M
Employees
50K
Daily Change %
-0.65%
5 Days Change
-2.29%
10 Days Change
-3.19%
30 Days Change
-7.84%
60 Days Change
-4.84%
Month to Day Change
-3.19%
Year to Day Change
5.00%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — LLY
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-09-10
Latest call per bank · past 12 months
HSBC
Reduce$940
-16.3% vs priceWells Fargo
Overweight$1,330
+18.4% vs priceCitigroup
Buy$1,600
+42.5% vs priceUBS
Buy$1,425
+26.9% vs priceBank of America
Buy$1,334
+18.8% vs priceMorgan Stanley
Overweight$1,347
+19.9% vs priceRBC Capital
Outperform$1,500
+33.6% vs priceJP Morgan
Overweight$1,400
+24.7% vs priceJefferies
Buy$1,350
+20.2% vs priceBarclays
Overweight$1,400
+24.7% vs priceDeutsche Bank
Buy$1,285
+14.4% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-10 | HSBC | Maintains | Reduce | $850 → $940 |
| 2026-08-07 | Truist Securities | Maintains | Buy | $1,370 → $1,376 |
| 2026-08-06 | Wells Fargo | Maintains | Overweight | $1,280 → $1,330 |
| 2026-08-06 | Cantor Fitzgerald | Maintains | Overweight | $1,350 → $1,410 |
| 2026-07-15 | Citigroup | Maintains | Buy | $1,500 → $1,600 |
| 2026-07-14 | Bernstein | Maintains | Outperform | $1,300 → $1,385 |
| 2026-07-13 | UBS | Maintains | Buy | $1,250 → $1,425 |
| 2026-07-13 | Guggenheim | Maintains | Buy | $1,235 → $1,273 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 36 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 5.7% below the 50-day MA ($1,183.64).
- Price vs 200-day MA: Trading 5.1% above the 200-day MA ($1,062.00).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-10.02) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($710.11) and high ($1,280.34).
LLY Price Chart
Loading chart for LLY…
Fundamentals
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; and BioArctic AB (publ) for new treatment. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
More in Drug Manufacturers - General
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.